Logo
x

Search

Subscribe Now

Novartis

PharmaShots Weekly Snapshots (September 16 – September 20, 2024)

PharmaShots Weekly Snapshots (September 16 – September 20, 2024)

  • September 20, 2024
Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer

Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer

  • September 18, 2024
Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) at ESMO 2024

Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) a...

  • September 16, 2024
Astellas’ Padcev Plus Keytruda Receives the EC’s Approval to Treat Advanced Urothelial Cancer

Astellas’ Padcev Plus Keytruda Receives the EC’s Approval to Treat Advanced Urothelial Cancer

  • August 28, 2024
Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disease (ASCVD) Risk

Novartis Reports Topline Data from P-III (V-MONO) Trial of Leqvio (Inclisiran) in Patients at Atherosclerotic Cardiovascular Disea...

  • August 28, 2024
Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

  • May 31, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.